REPRAT GAST 20MG GASTRO RESISTANT TABLET

Land: Kypros

Språk: gresk

Kilde: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Aktiv ingrediens:

PANTOPRAZOLE SODIUM SESQUIHYDRATE

Tilgjengelig fra:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATC-kode:

A02BC02

INN (International Name):

PANTOPRAZOLE

Dosering :

20MG

Legemiddelform:

GASTRO RESISTANT TABLET

Sammensetning:

PANTOPRAZOLE SODIUM SESQUIHYDRATE (8000001653) 22,575MG

Administreringsrute:

ORAL USE

Resept typen:

Εθνική Διαδικασία

Terapeutisk område:

PANTOPRAZOLE

Produkt oppsummering:

Νομικό καθεστώς: Χωρίς Ιατρική Συνταγή; PACK WITH 10 TABS IN BLISTER(S) (320020101) 10 TABLET - Εγκεκριμένο - Χωρίς Ιατρική Συνταγή

Informasjon til brukeren

COMPARATIVE TABLE OF PIL-EN VS PIL-GR
Package leaflet: Information for the patient
REPRAT Gast 20 mg gastro-resistant tablets
pantoprazole
Read all of this leaflet carefully before you start taking this
medicine
because it contains important information for you.
Always take this medicine exactly as described in this leaflet or as
your
doctor or pharmacist have told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See
section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse
after 2 weeks.
-
You should not take REPRAT Gast tablets for more than 4 weeks without
consulting a doctor.
What is in this leaflet
1.
What REPRAT Gast is and what it is used for
2.
What you need to know before you take REPRAT Gast
Φύλλο οδηγιών χρήσης: Πληροφορίες για
τον ασθενή
REPRAT Gast 20 mg γαστροανθεκτικά δισκία
παντοπραζόλη
Διαβάστε προσεκτικά ολόκληρο το φύλλο
οδηγιών χρήσης πριν αρχίσετε
να
παίρνετε
αυτό
το
φάρμακο,
διότι
περιλαμβάνει
σημαντικές
πληροφορίες για σας.
Πρέπει πάντοτε να παίρνετε αυτό το
φάρμακο ακριβώς όπως περιγράφεται
στο παρόν φύλλο οδηγιών χρήσης ή
σύμφωνα με τις οδηγίες του γιατρού ή
του φαρμακοποιού σας.
-
Φυλάξτε αυτό το φύλλο οδηγιών χρήσης.
Ίσως χρειαστεί να το
διαβάσετε ξανά.
-
Απευθυνθείτε στο φαρμακοποιό σας, εάν
χρειαστείτε περισσότερες
πληροφορίες ή συμβουλές.
-
Εάν παρατηρήσετε κάποια ανεπι

Preparatomtale

1.
NAME OF THE MEDICINAL PRODUCT
REPRAT Gast 20 mg Gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg pantoprazole as
pantoprazole sodium sesquihydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablets.
REPRAT Gast tablets are oval, yellow coloured gastro-resistant coated
tablets.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
REPRAT Gast is indicated for short-term treatment of reflux symptoms
(e.g. heartburn, acid
regurgitation) in adults.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Poso
l
o
g
y
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to
achieve improvement of
symptoms. Once complete relief of symptoms has occurred, treatment
should be discontinued.
The treatment should not exceed 4 weeks without consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous
treatment, the patient should be
instructed to consult a doctor.
_Spec_
_ _
_ i_
_ al_
_ _
_ popu_
_ _
_ l_
_ a_
_ ti_
_ ons_
_ _
_ _
No dose adjustment is necessary in elderly patients or in those with
impaired renal or liver
function.
_Paed_
_ _
_ i_
_ a_
_ t_
_ r_
_ i_
_ c popu_
_ _
_ l_
_ a_
_ ti_
_ on_
_ _
_ _
1
SUMMARY OF PRODUCT CHARACTERISTICS
Pantoprazole is not recommended for use in children and adolescents
below 18 years of age due
to insufficient data on safety and efficacy.
Me
t
hod of
ad
m
i
n
i
s
tr
a
ti
on
REPRAT Gast 20 mg gastro-resistant tablets should not be chewed or
crushed, and should be
swallowed whole with liquid before a meal.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance, or to any of the excipients
listed in section 6.1.
Co-administration with atazanavir (see section 4.5).
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed to consult a doctor if:

They have unintentional weight loss, anaemia, gastrointestinal
bleeding, dysphagia, persistent
vomiting or vomiting wi